Predicting Alzheimer disease from a blood-based biomarker profile

Neurology

Volumn 87, Issue 11, 2016, Pages 1093-1101

  Burnham, Samantha C ^a   Rowe, Christopher C ^b,c   Baker, David ^d   Bush, Ashley I ^e   Doecke, James D ^a   Faux, Noel G ^e   Laws, Simon M ^g   Martins, Ralph N ^g,i   Maruff, Paul ^j   Macaulay, S Lance ^a,h   Rainey Smith, Stephanie ^g,i   Savage, Greg ^k   Ames, David ^f   Masters, Colin L ^c   Wilson, William ^a   Villemagne, Victor L ^c  

^a CSIRO   (Australia)

^b AUSTIN HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e Academic Unit for Psychiatry of Old Age   (United States)

^f Department of Psychiatry ^*  (United States)

^g EDITH COWAN UNIVERSITY   (Australia)

^h CURTIN UNIVERSITY   (Australia)

ⁱ HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^j Scientific Division   (Australia)

^k MACQUARIE UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B; BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL CLASSIFICATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; ANALYSIS OF VARIANCE; BLOOD; BLOOD ANALYSIS; BRAIN; COGNITION; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; METABOLISM; NEUROPSYCHOLOGICAL TEST; ODDS RATIO; PSYCHOLOGY; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; BIOMARKERS; BLOOD CHEMICAL ANALYSIS; BRAIN; COGNITION; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; NEUROPSYCHOLOGICAL TESTS; ODDS RATIO; POSITRON-EMISSION TOMOGRAPHY;

EID: 84987641969     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003094     Document Type: Article

References (34)

1. Doecke JD, Laws SM, Faux N, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 2012;69:1318-1325.
2. O'Bryant SE, Xiao G, Barber R, et al. A serum proteinbased algorithm for the detection of Alzheimer disease. Arch Neurol 2010;67:1077-1081.
3. O'Bryant SE, Xiao G, Barber R, et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One 2011;6:e28092.
4. Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 2012;69:1310-1317.
5. Hye A, Riddoch-Contreras J, Baird AL, et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 2014;10:799-807.
6. Kiddle SJ, Thambisetty M, Simmons A, et al. Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One 2012;7:e44260.
7. Ashton NJ, Kiddle SJ, Graf J, et al. Blood protein predictors of brain amyloid for enrichment in clinical trials? Alzheimers Dement 2015;1:48-60.
8. Burnham SC, Faux NG, Wilson W, et al. A blood-based predictor for neocortical A beta burden in Alzheimer's disease: results from the AIBL Study. Mol Psychiatry 2014;19: 519-526.
9. Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009;21:672-687.
10. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 2011;77:333.
11. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246.
12. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
13. Lui JK, Laws SM, Li QX, et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis 2010;20:1233-1242.
14. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein-E by gene amplification and cleavage with HHAI. J Lipid Res 1990;31:545-548.
15. Burnham SC, Raghavan N, Wilson W, et al. Novel statistically-derived composite measures for assessing the efficacy of disease-modifying therapies in prodromal Alzheimer's disease trials: an AIBL Study. J Alzheimers Dis 2015;46:1079-1089.
16. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-1283.
17. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med 2010; 51:913-920.
18. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010;68:319-329.
19. Clark CM, Schneider JA, Mintun MM, et al. Phase III trial results for the amyloid PET imaging agent florbetapir F 18 (18F-AV-45): imaging to histopathologic correlations in an end-of-life human subject study. Alzheimers Dement 2010;6(suppl):S71.
20. Thurfjell L, Lundqvist R, Buckley C, Smith A, Sherwin P. Automated quantification of [18F] flutemetamol data: comparison with standard of truth based on histopathology. J Nucl Med 2013;54:302.
21. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-b plaques: a prospective cohort study. Lancet Neurol 2012;11:669-678.
22. Villemagne V, Doré V, Yates P, et al. En Attendant centiloid. Adv Res 2014:723-729.
23. Bernal-Rusiel JL, Greve DN, Reuter M, et al. Statistical analysis of longitudinal neuroimage data with linear mixed effects models. Neuroimage 2013;66:249-260.
24. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: The R Foundation for Statistical Computing; 2011. ISBN: 3-900051-07-0.
25. Liaw A, Wiener M. Classification and regression by randomForest. R News 2002;2:18-22. Available at: https://www.r-project.org/doc/Rnews/Rnews-2002-3.pdf. Accessed April 5, 2016.
26. Therneau T. A Package for Survival Analysis in S. R Package Version 2.37-4. Available at: https://cran.r-project.org/web/packages/survival/index.html. Accessed April 5, 2016.
27. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing the performance of scoring classifiers. Bioinformatics 2009;21:3940-3941.
28. Pinheiro J, Bates D, DebRoy S, et al; R Core Team. nlme: Linear and Nonlinear Mixed Effects Models. R Package Version 3.1-117. 2014. Available at: https://cran.r-project. org/web/packages/nlme/index.html. Accessed April 5, 2016.
29. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
30. Rowe CC, Bourgeat P, Ellis KA, et al. Predicting Alzheimer disease with b-amyloid imaging: results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing. Ann Neurol 2013;74:905-913.
31. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011;77:1619-1628.
32. Harrington KD, Lim YY, Ellis KA, et al. The association of A beta amyloid and composite cognitive measures in healthy older adults and MCI. Int Psychogeriatr 2013;25: 1667-1677.
33. Lim YY, Maruff P, Pietrzak RH, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2013;137:221-231.
34. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid b deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12:357-367.